Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441
NCT02479204 · Viatris Innovation GmbH · PHASE1 · terminated · last registry update 2025-09-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported” | – | Registry record, Viatris Innovation GmbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-15Results posted on the registry: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2026-07-07Phase 3 first posted: Vanda Pharmaceuticals, Ponesimod + Placebo (NCT07686081)
- 2026-07-01Results posted on the registry: Pfizer, Etrasimod + Etrasimod (NCT04173273)
- 2026-07-01Also stopped (terminated): Pfizer, Etrasimod + Etrasimod (NCT04173273)
- 2026-03-19Phase 3 first posted: Biogen, Diroximel Fumarate + Dimethyl Fumarate (NCT07483632)
- 2026-02-10Results posted on the registry: Bristol-Myers Squibb, Ozanimod (NCT05369832)
- 2026-02-10Also stopped (terminated): Bristol-Myers Squibb, Ozanimod (NCT05369832)
- 2026-01-23Phase 3 first posted: Vanda Pharmaceuticals, Ponesimod (NCT07362017)
- 2026-01-14Also stopped (withdrawn): Yale University, Etrasimod + Placebo (NCT06521762)
- 2025-12-31Results posted on the registry: Celgene, RPC1063 (NCT02531126)
- 2025-12-02Also stopped (withdrawn): Bristol-Myers Squibb, a drug against S1PR1 (NCT06181630)
- 2025-11-12Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab (NCT04353492)
- 2025-11-04Results posted on the registry: Celgene, Ozanimod (NCT03440372)
- 2025-11-04Also stopped (terminated): Celgene, Ozanimod (NCT03440372)
- 2025-10-23Phase 3 first posted: TG Therapeutics, Inc., Ublituximab + Placebo (NCT07220252)
- 2025-10-09Results posted on the registry: Celgene, Ozanimod (NCT03464097)
- 2025-10-09Also stopped (terminated): Celgene, Ozanimod (NCT03464097)
- 2025-10-01Phase 3 first posted: Viatris Innovation GmbH, Cenerimod + Placebo (NCT07201129)
- 2025-09-17Results posted on the registry: Celgene, Ozanimod (NCT03467958)
- 2025-09-17Also stopped (terminated): Celgene, Ozanimod (NCT03467958)
- 2025-08-29Results posted on the registry: Novartis Pharmaceuticals, Fingolimod 0.5mg (NCT04667949)
- 2025-08-17Also stopped (withdrawn): University Hospital, Antwerp, tolerogenic dendritic cells (tolDC) + Standard-of-care (NCT06715605)
- 2025-07-15Results posted on the registry: Pfizer, Etrasimod + Placebo (NCT04607837)
- 2025-06-12Also stopped (terminated): Celgene, RPC-1063 (NCT04140305)
- 2025-05-13Results posted on the registry: State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision